Creative BioMart to Present at BPS 2025 Annual Meeting | February 15-19, 2025

Recombinant Rhesus Monkey TNFRSF18 Protein

Cat.No. : TNFRSF18-1785R
Product Overview : Recombinant Rhesus monkey TNFRSF18 Protein (XP_014971033 ( aa.26-162)) was expressed in human HEK293 cells.
  • Specification
  • Gene Information
  • Related Products
  • Download
Description : Receptor for TNFSF18. Seems to be involved in interactions between activated T-lymphocytes and endothelial cells and in the regulation of T-cell receptor-mediated cell death. Mediated NF-kappa-B activation via the TRAF2/NIK pathway.
Source : HEK293
Species : Rhesus monkey
Form : PBS, pH7.4.
Purity : > 95 %
Applications : ELISA; WB; Immunogen
Storage : -80 centigrade, Avoid freeze/thaw cycle.
Concentration : 1 mg/mL
Tag : Non
Protein length : 26-162
Gene Name : TNFRSF18 TNF receptor superfamily member 18 [ Macaca mulatta (Rhesus monkey) ]
Official Symbol : TNFRSF18
Synonyms : TNFRSF18; tumor necrosis factor receptor superfamily; member 18; tumor necrosis factor receptor superfamily member 18; AITR; CD357; GITR; activation-inducible TNFR family receptor; glucocorticoid-induced TNFR-related protein; TNF receptor superfamily activation-inducible protein; GITR-D;
Gene ID : 699559
mRNA Refseq : XM_015115547.1
Protein Refseq : XP_014971033

Not For Human Consumption!

Inquiry

  • Reviews
  • Q&As

Customer Reviews (3)

Write a review
Reviews
12/20/2021

    This flexibility enables researchers like myself to tailor TNFRSF18 protein experiments to our unique needs, enhancing the reliability and relevance of the obtained results.

    03/05/2020

      Their commitment to delivering exceptional products and assisting with any challenges that may arise ensures a successful and rewarding experimental journey.

      10/01/2017

        The TNFRSF18 protein offered by the manufacturer is of exceptional quality, and it meets the rigorous standards necessary for my experimental needs.

        Q&As (5)

        Ask a question
        What are some current clinical trials involving TNFRSF18-targeted therapies in cancer treatment? 12/20/2022

        Clinical trials are investigating TNFRSF18 agonists, such as monoclonal antibodies, in combination with other cancer treatments in various cancer types.

        Are there any approved TNFRSF18-targeted therapies for cancer treatment? 06/29/2019

        As of my knowledge cutoff date in January 2022, there were no approved TNFRSF18-targeted therapies for cancer. However, this may have changed since then.

        Are there potential side effects associated with TNFRSF18-targeted therapies? 12/30/2018

        Side effects may include immune-related adverse events, similar to those seen with other immunotherapies, and can range from mild to severe.

        How can TNFRSF18-targeted therapies potentially improve cancer outcomes? 05/05/2018

        TNFRSF18-targeted therapies may enhance the body's immune response against cancer cells, leading to better tumor control and improved patient outcomes.

        Can TNFRSF18-targeted therapies be used in combination with other immunotherapies? 05/20/2016

        Yes, combination therapies involving TNFRSF18 agonists and other immunotherapies are under investigation to improve treatment efficacy.

        Ask a Question for All TNFRSF18 Products

        Required fields are marked with *

        My Review for All TNFRSF18 Products

        Required fields are marked with *

        0

        Inquiry Basket

        cartIcon
        logo

        FOLLOW US

        Terms and Conditions        Privacy Policy

        Copyright © 2025 Creative BioMart. All Rights Reserved.

        Contact Us

        • /
        • Service lnquiry:

        Stay Updated on the Latest Bioscience Trends